Clinical Trial Registration in Latin America and the Caribbean
Cochrane Colloquium, October 26th, 2007. São Paulo, Brazil
Minutes and Recommendations

Title: Regional contributions to the International Clinical Trials Registry Platform (ICTRP) initiative

Time and place: 14:00 hrs. – 16:00 hrs. Room: CADIZ, World Trade Center.

Participants: 23+ participants including: representatives from the Latin American and Caribbean Center on Health Sciences Information (BIREME/PAHO/WHO), government health and research institutions and national research registers (Brazil, Cuba, Colombia, Chile, India, Germany), members of the Scientific Board and International Advisory Board of the International Clinical Trial Register Platform (ICTRP), the coordinator of the ICTRP, the LATINREC register, and other technical experts. (List of participants)

Opening session

The meeting was opened and participants were welcomed by the Unit Chief of PAHO's Research Promotion and Development Unit (RC), Dr. Luis Gabriel Cuervo, and the Director of the Latin American and Caribbean Center on Health Sciences Information (PAHO/BIREME), Mr. Abel Packer.

Dr. Cuervo provided an overview of the global and regional developments since the Mexico Declaration, the consultations and launching of the ICTRP, and emphasized the developments of the past couple of years in the region, as well as PAHO's high-level advocacy to promote trial registration. Dr. Cuervo emphasized specific strategies that are under evaluation for the region including: a regional portal that allows trial registration; an open source ICTRP compliant software that will allow member countries to kickstart their national registers with a tool that allows customization yet offers compatible communications protocols, reducing duplication; a primary regional register that will collate information from the region, provide centralized data quality assurance, standardization and translation, feed into WHOs ICTRP Portal, and monitor and characterize registered research. PAHO will also work with member states to create incentives and promote a legal framework and the advocate for trial registration.

PAHO is the Regional Office of the World Health Organization (WHO) for the Region of the Americas (as the specialized organization for health of the Inter-American System), and as part of WHO one of its priorities is to identify and propose interventions that strengthen health research governance; trial registration has been repeatedly identified in different forums as instrumental in allowing proper health research governance and monitoring, and is considered an important tool to build public confidence and trust in health research.

The Meeting Objectives achieved were the following:

1. The participants discussed about the progress and activities carried out to promote clinical trials registration in Latin American and the Caribbean. Presentations were also made on a framework for a Primary Clinical Trials Register Model built on an "open source" software and the methodology to collect and disseminate information on clinical trials and feed the ICTRP.

2. The participants identified the best strategies of advocacy and promotion of the initiatives, and discussed the implementation of the Model, as well as the need to join efforts with other advocates and pioneers of registration in the Americas to build on collaboration, tap on the strengths of the different parties, and avoid duplication.

Agenda

The agenda was accepted as presented and guests introduced themselves.

1) *Presentation:* Advances and challenges in the Clinical Trial Registration in Latin American and the Caribbean, by Dr. Luis Gabriel Cuervo:

- Join activities XI World Congress of Public Health (2006) regarding Clinical Trials Registration: workshop, plenary and seminar
- BIREME reached an agreement among regional editors to require trial registration as from a set date, and raise awareness about it.
- PAHO's RC promoting debate, raising awareness, and engaging with stakeholders
- PAHOs RC participates in the Secretariat, and reports to the Global and Regional Advisory Committee in Health Research, and others addressing technical cooperation for trial registration
- Organizational support for the initiative:
    - It is included in WHO's agenda as an important strategy to improve transparency and guide health research policies
    - It is highlighted as instrumental for health research governance by PAHO and its member countries
    - Asking grantees, funding agencies, project sponsors, and ethics review committees to implement trial registration when appropriate
    - Engaging Institutional Review Boards/Ethics Review Committees, and the networks that bring them together

2) *Presentation*: PAHO Proposal of a Primary Clinical Trials Register Model for Latin America and the Caribbean, by Mr. Milton Lapidus (BIREME) and Mr. Rodrigo Senra (GPr Sistemas Ltda) under contract with PAHO/WHO.

Available at http://reddes.bireme.org/documentacao-dos-projetos/clinical-trials-1/draft-reports/vision-report-0.5/

3) *Discussion*:

- About the technical proposal: Primary Clinical Trials Register Model for Latin America and the Caribbean and the Register Portal Proposal, Moderator Dr. Trudo Lemmens, and

- How to identify best cooperation strategies for the promotion and development of the Primary Clinical Trials Register Strategies, Moderator Dr. José da Rocha Carvalheiro

The proposal prepared by BIREME and HSS/RC was well received and recommendations were made to consult it with existing registers and potential users of the software to see if it addresses their needs; PAHO (RC/BIREME) received very positive feedback and praise for conducting this consultation and demonstrating regional leadership

Schema map (Appendix III of the document): analysis of certified registers and fields were recognized as an added value for potential registries.

It is necessary to identify the best strategies of advocacy and promotion, and ensure the implementation of the agreed model establishing how to bring together the different initiatives and parties working on trial registration in the Americas to create strong partnerships and networking.

Follow up the development of the Regional Portal of Clinical Trials: Delivering a consulted proposal for the development of an open source software with voluntary participation of teams like the Centro Nacional de Ensayos Clínicos de Cuba, LatinREC, and representatives of the proposed country registers from Argentina, and Brazil. The proposal should encompass consultations for standardization, advocacy, and training. PAHO and BIREME should continue their joint and inclusive work in this matter. A map of the clinical trial registration in the region is needed. There is a perceived need to characterize and monitor the flows, procedures, regulations, and intents of registration in the Region of the Americas.

Conclusions

1. The workshop was perceived as successful and inclusive, with about 25 participants including representatives from research and government institutions and national registers (Argentina, Brazil, Cuba, Colombia, Chile, India, Germany), Iberoamerican Cochrane and LATINREC, members of the ICTRP Scientific Board and the International Advisory Board, other technical experts including people from other regions, BIREME and PAHO HSS/RC

2. There is a shared interest in achieving coherent trial registration, a coherent deployment of the initiatives, and better understanding research production in our Region
3. Agreement in the Conceptual Framework for a Primary Register
4. Favorable context for development in the Region
5. The register is not an end but a tool for adequate and timely access for access of information
6. Intellectual propriety rights: trade and patent tradition need to be addressed
7. There are some countries that have developed their own registry or require mandatory registration by ethics review committees; it is necessary to work in the Registration of Clinical Trials.
8. PAHO should continue to promote trial registration in compliance with the International Clinical Trials Registry Platform, which must include: 1) continued advocacy; 2) monitoring progress; 3) defining strategies for implementation; and 4) defining strategies for promoting adherence believes that PAHO should see the registry a means to an end (improving health and reducing inequities in health through the transparent conduct and reporting of research using human subjects), not an end in its own right, and to move over time to adding study results to the registry, not just key indicators drawn from the study protocol. PAHO should work in close cooperation with WHO in its work on clinical trial results reporting and on the impact of intellectual property rights and trade secret laws on the promotion of transparent research
9. Participants commended PAHO/BIREME for their efforts to avoid duplication, promote registration and inclusive collaboration.

Recommendations

Participants encouraged PAHO to proceed with the technical work required to establish a regional registry in close cooperation with country representatives, and to prepare for the required technical cooperation to implement the registry, promote adherence, and (eventually) include trial results reporting.
There is need to continue a high-level advocacy for the registry, include trial registration as a requirement for ethics review by Ethics Review Committees, and work in close cooperation with WHO in its work on clinical trial results reporting and on the impact of intellectual property rights and trade secret laws on the promotion of transparent research

Activities or lines of actions

1. Build on the momentum promoting further debate about the implementation of the ICTRP proposal in Latin America and the Caribbean, and the advocacy of ICTRP compliant trial registration
2. Plan ahead and reach constructive agreements; build on what has been already achieved, coordinate our work, avoid duplication, distribute responsibilities
3. The need of an open source tool to facilitate coherent and standardized trial registration, and yet allows customization (of data and workflows) to meet local needs

4. Allocation of resources for technical cooperation including strategies to enhance adherence and facilitate implementation of trial registration
5. There is an pressing need for the definition of the Universal Trial Registration Number by the World Health Organization
6. A mapping characterizing trial registration in member countries is needed. This would include registers, partners, regulations, implementation models and resources.
7. Advocacy, promoting adherence, monitoring progress, and defining strategies for implementation. For this it was proposed three strategies: a) Conceptual framework for a Primary Register, b) An open source tool to facilitate coherent and standardized trial registration, c) Technical cooperation including strategies for adherence and implementation, d) to be included in the PAHO Research Policy related to good practices
8. A proposal was made for follow up meetings to be organized in future Cochrane Colloquia.

The meeting adjourned.

Research Promotion and Development Unit.
Health Systems Strengthening Area (HSS/RC)
Pan American Health Organization | World Health Organization
525, 23 th Street, Washington, DC. N.W 20037
Tel: +1-202-974-3000 - Fax:
http://www.paho.org

BIREME | PAHO | WHO, PAHO IKM Area
Latin American and Caribbean Center on Health Sciences Information
Pan American Health Organization | World Health Organization
Rua Botucatu, 862 - Vila Clementino - 04023-901 São Paulo, Brasil Tel: 55-11-5576-9800 - Fax: 55-11-5575-8868
info@bireme.br | http://www.bireme.org

Participants

Clinical Trial Registration in Latin America and the Caribbean

Date: Friday, 26 October, 2007
Time: 14:00 hrs. To 16:00 hrs.
Room: CADIZ Valdés
Contact person: Abel L. Packer, Luis Gabriel Cuervo
e-mail; packerab@bireme.ops-oms.org, cuervolu@paho.org

Name

Dr. Xavier Bonfill Iberoamerican Cochrane Centre	Tel: Fax: E-mail
Dr. José da Rocha CARVALHEIRO Coordinador del Proyecto Innovación en Salud Fundación Oswaldo Cruz - FIOCRUZ Rio de Janeiro Brasil CAMPUS Sede: Av. Brasil, 4365 - Manguinhos, Rio de Janeiro CEP: 21040-360 Tel.:(0xx21) 2598-4242 |	Tel: Fax: E-mail jrcarval@fiocruz.br
Dr. Regina CASTRO Coordinadora de Comunicación Científica Centro Latinoamericano y del Caribe para Información en Ciencias de la Salud (BIREME) Rua Botucatú 862, Vila Clementino CEP.04023-062, São Paulo, SP, Brasil	Tel: (1-55-11) 5576-9800 Fax: (1-55-11) 5575-8868 E-mail: castrore@bireme.ops-oms.org
Dr. Luis Gabriel CUERVO AMORE Jefe de la Unidad de Promoción y Desarrollo de la Investigación (HSSRC) Organización Panamericana de la Salud 525 23rd St NW, Washington, DC 20037. USA	Tel: (202) 974 3135 Fax: (202) 974 3652 E-mail: cuervolu@paho.org

Dr. Itajaí DE ALBUQUERQUE
Advisory
Secretariat of Health, Technology and Strategic Inputs
Minister of Health
Brazil

Tel:
E-mail
ltajai.albuquerque@saude.gov.br

Dr. Jose DE LA GUARDIA
FIOCRUZ
Brazil

Tel:
Fax:
E-mail: jlaguadia@cict.fiocruz.br

Dr. Kay Dichersin
Professor
Director, Center for Clinical Trials

Tel: +1-(410) 502-4421
Fax: +1-(410) 955-4621
E-mail: kdickers@jhsph.edu

Dr. Marcelo GARCIA DIEGUEZ
Coordinator, Argentine branch of LATINREC.
Argentine Collaborating Branch of the Iberoamerican Cochrane Network (CIE, Academia Nacional de Medicina), Buenos Aires, Argentina
Tucuman 419 – 800
Bahia Blanca, Argentina

Tel: +54 9291 6425713 (movil)
+54 291 4557877 (trabajo de 900 a 1600)
Fax:
E-mail: gdieguez@criba.edu.ar, mgdieguez@uns.edu.ar

Dr. Davina GHERSI
Geneva. Coordinator. International Clinical Trials Registry Platform
Department of Research Policy and Cooperation (RPC/IER),
World Health Organization,
Avenue Appia,
CH-1211 Geneva 27,
Switzerland.

Tel No : 41 22 7914401
Fax No : 41 22 7914169
Mob: +41 792 021829
E-mail: ghersid@who.int

Dr. Moisés GOLDBAUM
Departamento de Medicina Preventiva
Faculdade de Medicina da USP
Av. Dr. Arnaldo, 455 - 2º andar
01246-903 São Paulo Brasil

Tel55.11.30617084:
Fax: 55.11.30617444
E-mail: mgoldbau@usp.br

Dr. Ma. Cristina GUIMARAES
ICICT/FIOCRUZ
Instituto de Comunicaçao e Informaçao Cientifica e Tecnologica em Saúde

Tel
Fax:
E-mail: cguima@cict.fiocruz.br

Mr. Milton LAPIDU
Centro Latinoamericano y del Caribe para Información en Ciencias de la Salud (BIREME)
Rua Botucatú 862, Vila Clementino
CEP.04023-062, São Paulo, SP, Brasil

Tel: (1-55-11) 5576-9800
Fax: (1-55-11) 5575-8868
E-mail: lapidomi@bireme.ops-oms.org

Dr. John Lavis
PAHO/Advisory Committee in Health Research, President
Canada Research Chair in Knowledge Transfer and Exchange
Associate Professor, Clinical Epidemiology and Biostatistics,
McMaster University
Health Science Centre, Room 2D3
1200 Main St. West
Hamilton, ON, Canada
L8N3Z5

Tel (905) 525-9140 x 22907
E-mail: lavisj@mcmaster.ca

Dr. Trudo LEMMENS
PAHO/Advisory Committee in Health Research, Member
Associate Professor
Faculty of Law, University of Toronto
78 Queens Park Crescent
Toronto, Ontario M5S 2C5
Canada

Tel:
E-mail:
Trudo.lemmens@utoronto.ca

Dr. Abel PACKER
Director
Centro Latinoamericano y del Caribe para Información en Ciencias de la Salud (BIREME)
Rua Botucatú 862, Vila Clementino
CEP.04023-062, São Paulo, SP, Brasil

Tel: (1-55-11) 5576-9800
Fax: (1-55-11) 5575-8868
E-mail: packerab@bireme.ops-oms.org

Dr. Ulysses Panisset
Department of Research Policy and Cooperation (RPC/IER),
World Health Organization,
Avenue Appia,
CH-1211 Geneva 27,
Switzerland.

Tel No :
Fax No :
E-mail:

Dr. Analía PORRAS
Consultora
Unidad de Promoción y Desarrollo de la Investigación (HSSRC)
Organización Panamericana de la Salud
525 23rd St NW, Washington, DC 20037. USA

Tel: (202) 974-3114
Fax: : (202) 974 3652
E-mail: porrasan@paho.org

Dr. Ludovic REVEIZ
Coordinador Unidad De Gestión/Research Project Unit Manager
Instituto de Investigación/Sanitas Research Institute
Fundación Universitaria Sanitas
Avenida Carrera 68 No. 22 A - 30
Bogotá, Colombia.

Tel: (57) 1 222 1500 ext 116
Fax:
E-mail: lureveiz@colsanitas.com

Dr. Rodrigo Alejandro SALINAS
PAHO/Advisory Committee in Health Research, Member
Asesor, Departamento de Estudios
Ministerio de Salud
Mac Iver, 541 2do piso
Santiago, Chile

Tel: + (56) 2 574 0194
Fax: + (56) 2 638 3562

E-mail: rsalinas@minsal.gov.cl

Mr. Rodrigo SEMRA
Consultant

Tel:
Fax:
E-mail:

Dr. Prathap THARYAN
Coordinator South Asian Cochrane Network
Christian Medical College
Vellore 632002
Tamil Nadu, India

Tel: +91 416 2284499 /2284505
Fax: + 91 416 2260085
E-mail : prathap@cmcvellore.ac.in

Mrs. Ania TORRES POMBERT
Centro Nacional Coordinador de Ensayos Clíniocs (CENCEC)
Calle 200 y 21 Atabey
Cuba

Tel: 53 271 8342
Fax: 537 2720653
E-mail ania@cencec.sld.cu
map@infomed.sld.cu

Mrs. América VALDÉS MORALES
Diseminación de Información en Investigación
Unidad de Promoción y Desarrollo de la Investigación (HSS/RC)
Organización Panamericana de la Salud
525 23rd St NW, Washington, DC 20037. USA

Tel: (202) 974-3864
Fax: (202) 974 3874
E-mail: valdesam@paho.org

Clinical Trials Register Platform for Latin America and theCaribbean

Vision Report

Version 0.4 – October 2007

Project specification by Rodrigo Senra (GPr Sistemas Ltda) under contract with BIREME/PAHO/WHO under the supervision of BIREME, with Abel L. Packer as supervisor and Milton Lapido in charge of the technical project. This report was revised and commented by Regina C. Figueiredo Castro, also from BIREME/PAHO/WHO.

1 Introduction

The World Health Organization (WHO) Registry Platform is a project within the World Health Organization, involving the Research Policy & Cooperation Department (RPC) in the Information, Evidence and Research cluster (IER). The mission of the WHO Registry Platform is to ensure that a complete view of research is accessible to all those involved in health care decision making, improving research transparency and strengthening the validity and value of the scientific evidence base.

The WHO has been urging research institutions and companies to register all medical studies that test treatments on human beings. A trial register lists key administrative and scientific information about planned, ongoing, and completed trials, sufficient to identify that trial's existence. There are several registers of clinical trials around the world but little coordination among them.

The Registry Platform seeks to bring participating registers together in a global network to provide a single point of access to the information stored in them. The Registry Platform is not a register itself, but rather provides a set of standards for all registers. Besides standardizing what must be reported to register a trial, and implementing a unified search system, there is a third important goal: achieving a global trial identification system that confers a unique reference number on every qualified trial.

The International Clinical Trials Registry Platform (ICTRP) is a WHO project to establish norms and standards upon which international trial registration can take place ethically and scientifically. The main components of the platform are: (i) A Register Network; (ii) a one-stop search portal for searching registers worldwide; and (iii) norms and standards. At present, ICTRP integrates the following registries: *Australian Clinical Trials Register* (Australia, New Zealand), *ISRCTN* (England), *Chinese Clinical Trial Register – ChiCTR* (China), *Clinical Trials Registry* (India) and *ClinicalTrials.gov* (USA).

In August 2006, at Rio de Janeiro/Brazil, adherence to ICTRP was discussed in a workshop during the *8th Brazilian Congress on Collective Heath* and the *11th World Congress on Public* Health. At the opening session of the workshop, were present: Ida Sim, WHO project coordinator, Moisés Goldbaum, Secretary of Science, Technology and Strategic Resources of the Ministry of Health (SCTIE/MS), Luis Gabriel Cuervo, Coordinator of PAHO's Health Research Support Unity, Susanne Serruya, Director of DECIT/SCTIE/MS, José da Rocha Carvalheiro, member of ICTRP's *International Advisory Board,* Cristiane Quental, technician from FIOCRUZ's Technology Management Coordination and Abel L. Packer, BIREME/PAHO/WHO Director.

As a direct consequence of the workshop, starting from 2007, *BIREME/PAHO/WHO* demanded that all authors of publications related to clinical trials should submit their work to an ICRTP certified Register prior to acceptance. This report represents another concrete step towards the realization of a Clinical Trials Register Platform for LAC.

2 Concepts and Goals

There are many definitions of clinical trials. However, they are generally considered to be biomedical or health-related research studies in human beings that follow a predefined protocol.

Registration of clinical trials facilitates the dissemination of information among clinicians, investigators, researchers, care providers, sponsors, institutional review boards/independent ethics committees and trial participants (patients). It helps to assure trial participants that the information that accrues as a result of their altruism will become part of the public record. Therefore, the purpose of a clinical trials registry (or register) is to promote the public good by ensuring that everyone can find key information about every clinical trial whose principal aim is to shape medical decision-making.

Quoting the Ottawa Group Report [14], the rationale behind allowing public access to trial protocol information includes the following benefits:

- Minimise known risks and potential harm arising from unnecessary exposure to previously tested interventions;
- Accelerate research by making knowledge available about prior experiences with interventions;
- Identify and deter unnecessary duplication of research and publications;
- Identify and deter selective reporting of research (reporting biases);
- Provide a means of comparing the original protocol upon which ethics approval was based with the study as it was carried out;
- Enhance collaboration among researchers by informing them of ongoing trials.

Only an orchestrated network of collaborative Clinical Trials Registers will be capable of materializing these goals.

3 Platform Architecture

The WHO Network of Collaborating Clinical Trial Registers (The Register Network) provides a forum for registers to exchange information and work together to establish best practices for clinical trial registration. ICTRP defines the following components of the Register Network:

- WHO Central Repository (Reference Database)
- WHO Search Portal
- WHO Collaborating Registers:
  - Contributing Registers:
    - Primary Registers (provides data directly to the Central Repository)
    - Partner Registers (provides data indirectly to the Central Repository)
  - Non-contributing Registers (do not submit data to the Central Repository)
- Non-collaborating Registers (do not belong to the Register Network)

Any clinical trial register that registers trials prospectively; that is, before the first participant is recruited, can be a Collaborating Register in the Register Network. The non-contributing registers category allows a register to be included in the Register Network even if they do not meet one or more of the criteria for a Contributing Register. This architecture is depicted in Figure 1.



Figure 1 – Clinical Trials Register Architecture

4 Project Requirements

Clinical Trial Registries built upon our platform must adhere to the following requirements:

- register clinical trials data records
- provide a unified and integrated record search mechanism
- adhere to WHO/ICTRP guidelines
- allow operation and customization, independently from a central register
- global coherence and integration between registries

Each of these topics should be examined in greater detail.

4.1 Clinical Trials Registration

The two important aspects of clinical trials registration are: *what to register* and *how to do it* ? The answer to the first question lies on the data schema definition, the answer to the second is the registration protocol and interface.

The data schema supported in this proposal is divided in two sections: mandatory and customized. A detailed field list of the mandatory schema is defined in Appendix I of this report. It encompasses all the fields defined by ICTRP Trial Registration Data Set [2]. All fields in the mandatory section are required. The customized section allows register users to expand the schema to accommodate local, regional, and national needs. In Appendix II and III of this report we present a compilation of fields present in other Registries. This compilation provides input for the discussion about the existence (or not) of a third section: mandatory trial registration data set for LAC.

In addition to the mandatory sections, register users will be capable of selecting field definitions from a set of suggestions, compiled from Appendix III. Thus, customized record section will be composed by accepted field suggestions and custom field definitions. Ideally, there will be no need for custom field definitions. There are many advantages in reusing field definitions: (i) quicker and less error-prone record schema definition; (ii) better data compatibility and interoperability; (iii) richer and semantic-aware distributed searches. Nevertheless, register users will be given the tools to define custom fields for the customized sets that are not present in the mandatory sections neither in the suggestion set. This workflow is depicted in Figure 1.



Figure 2 – Proposed Trial Record Data Schema Definition Workflow

Semantic record annotation will also be supported. Following WHO's guidelines, 4 fields from the WHO mandatory data set describe the trial's scientific nature: *Conditions, Interventions, Primary* and *Secondary Outcomes* . These fields should be coded in the standard MeSH vocabulary to standardize the description of trials and allow accurate searches. We propose the adoption of BIREME/PAHO/WHO DeCS [8] to enhance annotation. DeCS or *Health Science Descriptors* is a structured vocabulary where each term from the vocabulary is mapped in three languages: Portuguese, Spanish and English. Moreover, DeCS is used to index several digital libraries improving precision in queries.

Only after the definition of the trial record data schema, register users will be allowed to enter record trials to the register. Record data input will be done in phases, corresponding to the section of the schema: mandatory, custom-suggested, custom-defined.

Moreover, each data record will be associated with a state from the following set: draft, pending, rejected and published. A new record is created in the draft state, and remains in this state while being edited by the user. After the mandatory field set is filled-in and validated, the user will be allowed to command a state transition (submission) to the pending state.

Submission will trigger an automated mechanism to obtain the *Universal Trial Reference Number* (UTRN) from WHO. UTRN would facilitate the unique clinical trials identification. The intention is that this number becomes part of the trial's identity. The UTRN would be used whenever information about the trial is communicated, should be verifiable and have built-in error-detecting logic.

UTRN should have the following properties:

- Enables unique identification of individual trials and their publications even if they are registered in multiple registries with multiple IDs;
- Enables global checking for duplication across multiple certified registries rather than within a single registry;
- Minimizes potential confusion introduced by multiple IDs from different registries;
- Easily recognizable;
- Internationally uniform.

There are two possible outcomes from the record trial submission: the record state will be either rejected or published. Either way, the responsible user will be notified by an e-mail notification and a news alert accessible at the user's home page inside the portal register. If the submission was rejected, the user will be able to examine the reason, apply corrective measures and re-submit the record. If the submission was published, the record has a valid UTRN and will show up in queries to the unified record search mechanism. It is important to notice that, at the present time, WHO has not yet released the protocol specification for UTRN distribution.

4.2 Record Search Mechanism

Clinical trials are one of the most important sources of scientific evidence on the safety and effectiveness of health interventions. Access to information about ongoing, completed and published clinical trials is essential for informed decision-making. Researchers, research funders, policy-makers, medical practitioners, patients and the general public need such information, to help guide research or to make treatment decisions. Therefore, a powerful, reliable and easy-to-use search mechanism is crucial.

Each register instance will be able to create its own database of information sources, according to BIREME/PAHO/WHO decentralized model. When a user issues a query at a register instance, the search activity will span through all information sources present at the register instance, including the register instance itself. An information source can be another register instance or any other information provider or search engine. The goal is to implement a flexible, distributed, extensible and scalable search mechanism.

There are three devised types of search: (i) logic search expression (using boolean connectors such as AND, OR, NOT) ; (ii) advanced search (taking advantage of specific field-sensitive information); (iii) browsing by category (initially restricted to local data).

The diversity of search mechanisms is necessary to satisfy different user demands: simple and quick query, specific and focused query, exploratory browsing.

4.3 WHO/ICTRP guidelines

The exact procedure to accomplish automatic protocol registration is not public documented yet at the WHO/ICTRP Portal [7]. We quote from ICTRP:

> "*Discussions in relation to how the UTRN might be implemented are ongoing. Regular updates will be posted to this website.*"
>
> "The WHO will start assigning UTRNs when the Registry Platform's global deduplication processes are finalized and implemented. We are currently developing guidance on the use of the UTRN. Please check back here periodically for updates. Last update: 19 June 2007"

BIREME/PAHO/WHO project members should contact WHO/ICTRP representatives to clarify the matter. The only information available so far, regarding UTRN obtention, is that a set of *web services* will be available for handling requests automatically.

4.4 Independent Operation and Customization

The end product of the Clinical Trials Register Platform will be a cross-platform software artifact called *Register Instance* or *Register Portal*. Each instance, once deployed, will be self-sufficient, meaning that the institution responsible for installing and running the instance will have autonomy to manage it, configure it, feed it with data and open it to public. However, UTRN obtention and distributed searches will depend on interaction with other instances or registries.

Furthermore, each instance will provide facilities for local interface customization (look-and-feel) and local information publication. Interface customization consists of changing page layouts, document templates, text formatting and any other form of decoration. Local Information publication will be made available by means of *folders*, *files, news* and *document* objects; these building blocks can be used *ad* hoc to build a hierarchical documentation structure.

4.5 Coherence and Integration between Registers

Coherence among registries is achieved because they all share the same structure, the same feature set, and the same inter-operation protocols. Two means of cooperation were already discussed: the distributed record search mechanism and UTRN obtention protocol. There are two other means of integration: *bulk record transfer* and *news syndication*.

Bulk record transfer is a mechanism to exchange (import and export) record sets as a single operation between registries. Two common use cases that justify the need for bulk record transfer are: (i) to incorporate data from legacy systems; (ii) when one register is to be deactivated and another register will be in charge of preserving and serving its data. WHO is working with CDISC [9] to define an XML standard for Registration Data Set interchange, consisting of an extension of the CDISC Object Data Model (ODM) and linked to HL7, BRIDG, caBIG. The CDISC Submission Data Standards (SDS) Team has released a draft version of the SDTM Implementation Guide (SDTMIG) for Human Clinical Trials, Version 3.1.2, for public review and comment. Reviewers are asked to submit comments by the close of business on Friday, September 28, 2007. A final version is expected to be available in early 2008.

In general, syndication means the distribution a news article through a syndicate - in this case an RSS feed - for publication in a number of newspapers or periodicals simultaneously. In our case, each register instance can act as a provider or as a consumer (or both) of news related to clinical trials. There will be an interface for administrative users to define external news source feeds. Symmetrically, if a remote instance defines the local instance as a source feed, it will receive transparent and implicit access to all local news objects published in the local instance.

5 Implementation Strategy and Methodology

There are two strategies to implement Clinical Trial Registries. The first one is to design and implement a light-weight portal from scratch, specifically designed to the task of clinical trials registration. The second strategy is to reuse and adapt code from a web content management system (CMS). Considering that the former strategy takes longer and it is more error prone, we propose the adoption of the latter.

A CMS is a web application designed to make it easy for non-technical users to add, edit and *manage* a website. Not only do content management systems help website users with content editing, they also take care of a lot of "behind the scenes" work such as:

- automatically generating navigation elements
- making content searchable and indexable
- keeping track of users, their permissions and security settings
- associating a publication workflow to content

These processes must be adapted to conform with the requirements and goals described in section 2. Moreover, it is desirable that the chosen CMS infra-structure satisfies the additional criteria:

- easy to install
- easy to use
- internationalization (i18n) of interface and content
- comply with accessibility standards
- be an open source effort
- offer world-wide community support
- be extensible
- be cross-platform

As for methodology, we embrace the open source *modus operandi* that consists of: a public mailing list for project discussions, public and integrated bug tracking/issue tracking/project management system and an open access source-code repository with version control support. These steps were already taken, and the infra-structure setup is ready.

6 Schedule

Considering the open-source based CMS systems available and their supported features, we enumerate the following list of customization activities to achieve the goals described in section 2:

Activity	**Description**	**Time frame**
1) Data modeling	define the list of available operations to portal users. Such as: a) create users; b) create information sources for searches; c) create news sources; d) create news items; e) create trials; f) perform queries; g) create local content and documentation (folders, documents and files)	3 weeks
2) Role modeling	define user roles and their respective scope of allowed operations. *Trialist* and *Administrator* are two predefined roles.	1 week
3) DDL Interface	create a adaption layer over the CMS native *data definition language* (DDL) to accommodate the clinical trials schema described in Appendix I (mandatory) and II (suggested). Each portal instance will have the minimal dataset defined by default. And the DDL interface will be made available to authorized users to augment the schema with fields from the suggested set (also defined by default) or to create their on custom fields.	4 weeks
4) ISIS bridge	adapt the CMS to use ISIS instead of its native storage system.	8 weeks
5) IAH integration	incorporate BIREME/PAHO/WHO *Interface for Access on Health Information* (IAH) to accomplish distributed queries.	3 weeks
6) DeCS integration	interoperate with DeCS to allow semantic annotation.	2 weeks
7) Bulk data exchange	implement data translation to and from XML layout.	2 weeks
8) WHO UTRN protocol	implement UTRN negotiation protocol	3 weeks

Table 1 – *Preliminary Activity Schedule*

7 Related Work

There are several registries in operation and some have been acknowledge by WHO ICTRP as primary registries. These efforts are documented in Table 2, extracted from WHO List of Registers [11].

Register Identification	URL	Status
Australian Clinical Trials Registry	http://www.actr.org.au/	Primary WHO Register
Chinese Clinical Trial Register (ChiCTR)	http://www.chictr.org/	Primary WHO Register (final stages of development)
Clinical Trials Registry - India	http://www.ctri.in/	Primary WHO Register (first trial has yet to be registered)
ISRCTN	http://www.controlled-trials.com/isrctn/	Primary WHO Register
ClinicalTrials.gov	http://www.clinicaltrials.gov	NOT a Primary Who Register (included in WHO Search Portal)
European Leukemia Trial Registry - ELTR	http://www.leukemia-registry.eu/	Partner Register (NOT included in WHO Search Portal)
Centre for Clinical Trials, Chinese University of Hong Kong	http://www.cct.cuhk.edu.hk/eng/services/info.html	Potential Contributing Registers (NOT included in WHO Search Portal)
Clinical Trial Database of the University Hospital Freiburg	http://www.zks.uni-freiburg.de/uklreg/php/index_en.php	Potential Contributing Registers (NOT included in WHO Search Portal)
German Somatic Gene Transfer Clinical Trial Database	http://www.dereg.de/	Potential Contributing Registers (NOT included in WHO Search Portal)
HIV/AIDS, Tuberculosis and Malaria Clinical Trial Registry (ATM Registry)	http://www.mrc.ac.za/cochrane/cochrane.htm	Potential Contributing Registers (NOT included in WHO Search Portal)
HKClinicalTrials.com	http://www.hkclinicaltrials.com/	Potential Contributing Registers (NOT included in WHO Search Portal)
Latin American Clinical Trials Register (LatinRec)	http://www.latinrec.org/	Potential Contributing Registers (NOT included in WHO Search Portal)
Registro Público Cubano de Ensayos Clínicos	http://registroclinico.sld.cu	Potential Partner Register
National Swedish Competence Centre for Musculoskeletal Disorders	http://nko.se/en/	Potential Contributing Registers (NOT included in WHO Search Portal)
South African National Clinical Trial Register (SANCTR)	http://www.sanrr.gov.za/	Potential Contributing Registers (NOT included in WHO Search Portal)
Sri Lanka Clinical Trials Registry	http://www.slctr.lk/	
University Hospital Medical Information Network (UMIN)	http://www.umin.ac.jp/	Potential Contributing Registers (NOT included in WHO Search Portal)

Table 2 – *Clinical Trial Registers*

8 Final Remarks

This report is still a preliminary vision for a Clinical Trial Register Platform for LAC. However, it collects and presents valuable information to accomplish the task and foster further discussion and more detailed specifications. Future versions of this document will give further information about lacking details such as: data preparation and how the search and retrieval engine is supposed to work.

9 Bibliographic References

1. Is This Clinical Trial Fully Registered?: A Statement from the International Committee of Medical Journal Editors. Catherine De Angelis, MD, MPH; Jeffrey M. Drazen, MD; Frank A. Frizelle, MBChB, MMedSc, FRACS; Charlotte Haug, MD, PhD, MSc; John Hoey, MD; Richard Horton, FRCP; Sheldon Kotzin, MLS; Christine Laine, MD, MPH; Ana Marusic, MD, PhD; A. John P.M. Overbeke, MD, PhD; Torben V. Schroeder, MD, DMSc; Harold C. Sox, MD; and Martin B. Van Der Weyden, MD. *http://www.icmje.org/clin_trialup.htm*
2. Trial Registration Data Set (WHO). http://www.who.int/ictrp/data_set/en/.
3. Service of U.S. National Institutes of Health, developed by the National Library of Health. http://www.clinicaltrials.gov
4. International Clinical Trials Registry Platform Search Portal. http://www.who.int/trialsearch/
5. Australian Clinical Trials Registry (ACTR). http://www.actr.org.au/
6. The Universal Trial Reference Number (UTRN). http://www.who.int/ictrp/utrn/en/
7. BIREME/PAHO/WHO DeCS - Health Science Descriptors. http://bvsmodelo.bvsalud.org/php/level.php?lang=en&component=27&item=1
8. Clinical Data Interchange Standards Consortium. http://www.cdisc.org/
9. Registro Latino Americano de Ensayos Clinicos en Curso. http://www.latinrec.org/
10. List of Registers. http://www.who.int/ictrp/network/list_registers/en/index.html
11. CUERVO, L.G.; VALDÉS, A.; CLARK, M.L. El registro internacional de ensayos clínicos. Revista Panamericana de Salud Pública, ano 85, v.19, n.6, jun 2006. Editoria
12. International Standard Randomised Controlled Trial Number (ISRCTN) – UK Search Register. http://www.controlled-trials.com/isrctn/applications/isrctn_data_items.htm
13. Clinical Trials Register – Índia (CTRI) Medical Institute of Medical Statistics. http://61.17.42.236/Clinicaltrials/trials_jsp/index.jsp
14. Krleža-Jeric K, Chan A-W, Dickersin K, Sim I, Grimshaw J, Gluud C for the Ottawa Group. The Ottawa Statement, Part One: Principles for international registration of protocol information and results from human trials of health-related interventions.
15. The Ottawa Group. Draft - The Ottawa Statement, Part Two: Principles of operationalisation for international trial registration.

Appendix I - Minimal Trial Registration Data Set

This section presents the minimal trial registration data set (version 1.0) defined by the International Clinical Trials Registry Platform (ICTRP) at WHO [2]. All fields described here are mandatory.

The schema below matches ICMJE proposal [1] specified at a meeting convened by the WHO in April 2005, the only difference is that ICMJE proposal suggested a boolean (true or false) *research ethics review* field documenting if the study, at the time of registration, received appropriate ethics committee approval. This field was replace by *Countries of Recruitment* field in the final ICTRP WHO standard. Therefore, the *research ethics review* field was moved to the additional non-mandatory field list, described in Appendix II.

1 Primary Register and Trial ID #

Name of Primary Register, and the unique ID number assigned by the Primary Register to this trial.

2 Date of Registration in Primary Register

Date when trial was officially registered in the Primary Register.

3 Secondary ID#s

Other identifying numbers and issuing authorities besides the Primary Register, if any. Include the sponsor name and sponsor-issued trial number (e.g., protocol number) if available. Also include other trial registers that have issued an ID number to this trial. There is no limit on the number of Secondary ID numbers that can be provided.

4 Source(s) of Monetary or Material Support

Major source(s) of monetary or material support for the trial (e.g., funding agency, foundation, company).

5 Primary Sponsor

Name the individual, organization, group or other legal entity which takes responsibility for initiating, managing and/or financing a study. The Primary Sponsor is responsible for ensuring that the trial is properly registered. The Primary Sponsor may or may not be the main funder

6 Secondary Sponsor(s)

Additional individuals, organizations or other legal persons, if any, that have agreed with the primary sponsor to take on responsibilities of sponsorship.A secondary sponsor may have agreed:

- to take on all the responsibilities of sponsorship jointly with the primary sponsor; or
- to form a group with the primary sponsor in which the responsibilities of sponsorship are allocated among the members of the group; or
- to act as the sponsor's legal representative in relation to some or all of the trial sites; or
- to take responsibility for the accuracy of trial registration information submitted.

7 Contact for Public Queries

Email address, telephone number, or postal address of the contact who will respond to general queries, including information about current recruitment status

8 Contact for Scientific Queries

Email address, telephone number, or postal address, and affiliation of the person to contact for scientific queries about the trial (e.g., principal investigator, medical director employed by the sponsor). For a multi-center study, enter the contact information for the lead Principal Investigator or overall scientific director.

9 Public Title

Title intended for the lay public in easily understood language.

10 Scientific Title

Scientific title of the study as it appears in the protocol submitted for funding and ethical review. Include trial acronym if available.

11 Countries of Recruitment

The countries from which participants will be, are intended to be, or have been recruited.

12 Health Condition(s) or Problem(s) Studied

Primary health condition(s) or problem(s) studied (e.g., depression, breast cancer, medication error). If the study is conducted in healthy human volunteers belonging to the target population of the intervention (e.g., preventative or screening interventions), enter the particular health condition(s) or problem(s) being prevented. If the study is conducted in healthy human volunteers not belonging to the target population (e.g., a preliminary safety study), an appropriate keyword will be defined for users to select.

13 Intervention(s)

Enter the specific name of the intervention(s) and the comparator/control(s) being studied. Use the International Non-Proprietary Name if possible (not brand/trade names). For an unregistered drug, the generic name, chemical name, or company serial number is acceptable. If the intervention consists of several separate treatments, list them all in one line separated by commas (e.g., "low-fat diet, exercise").

The control intervention(s) is/are the interventions against which the study intervention is evaluated (e.g., placebo, no treatment, active control). If an active control is used, be sure to enter in the name(s) of that intervention, or enter "placebo" or "no treatment" as applicable.

For each intervention, describe other intervention details as applicable (dose, duration, mode of administration, etc)

14 Key Inclusion and Exclusion Criteria

Inclusion and exclusion criteria for participant selection, including age and sex.

15 Study Type

A single arm study is one in which all participants are given the same intervention. Trials in which participants are assigned to receive one of two or more interventions are NOT single arm studies. Crossover trials are NOT single arm studies.

A trial is "randomized" if participants are assigned to intervention groups using a method based on chance (e.g., random number table, random computer-generated sequence, minimization, adaptive randomization).

16 Date of First Enrollment

If the trial is being registered after recruitment of the first participant record actual date of Anticipated date of enrollment of the first participant.

17 Target Sample Size

Number of participants that this trial plans to enroll.

18 Recruitment Status

Recruitment status of this trial.

- Pending: participants are not yet being recruited or enrolled at any site
- Active: participants are currently being recruited and enrolled
- Temporary halt: there is a temporary halt in recruitment and enrollment
- Closed: participants are no longer being recruited or enrolled

19 Primary Outcome(s)

Outcomes are events, variables, or experiences that are measured because it is believed that they may be influenced by the intervention. The Primary Outcome should be the outcome used in sample size calculations, or the main outcome(s) used to determine the effects of the intervention(s).

Enter the names of all primary outcomes in the trial as well as the pre-specified timepoint(s) of primary interest. Be as specific as possible with the metric used (e.g., “% with Beck Depression Score > 10 ”rather than just “depression”).

20 Key Secondary Outcomes

Secondary outcomes are events, variables, or experiences that are of secondary interest or that are measured at timepoints of secondary interest. A secondary outcome may involve the same event, variable, or experience as the primary outcome, but measured at timepoints other than those of primary interest (e.g., Primary outcome: all-cause mortality at 5 years; Secondary outcome: all-cause mortality at 1 year, 3 years), or may involve a different event, variable, or experience altogether (e.g., Primary outcome: all-cause mortality at 5 years; Secondary outcome: hospitalization rate at 5 years).

Enter the name and timepoint(s) for all secondary outcomes of clinical and/or scientific importance. Be as specific as possible with the metric used (e.g., “% with Beck Depression Score > 10” rather than just “depression”).

Appendix II – Additional Fields

This section enumerates fields adopted by several Clinical Trials Registries [1, 3] that are either not included in the minimal data set presented in Appendix I or simply have a different name but similar (equivalent / superset / subset) definition. These field definitions may be useful to support record exchange activities and services.

Research ethics review

Has the study at the time of registration received appropriate ethics committee approval (yes/no)? (It is assumed that all registered trials will be approved by an ethics board before commencing.)

Study Type

Nature of the investigation. Select one.

- Interventional: studies in human beings in which individuals are assigned to receive specific interventions. Subjects may receive diagnostic, therapeutic or other types of interventions. The
- assignment of the intervention may or may not be random. The individuals are then followed and biomedical and/or health outcomes are assessed.
- Observational: studies in human beings in which biomedical and/or health outcomes are assessed in a pre-defined group of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
- Expanded Access: records describing the procedure for obtaining an experimental drug or device for patients who are failing on currently available treatments for their condition and also are unable to participate in ongoing clinical trials. Expanded Access records are used to register all types of non-protocol access to experimental treatments, including protocol exception, single-patient IND, treatment IND, compassionate use, emergency use, continued access and parallel track.

Investigational New Drug Application (IND)/Investigational Device Exemption (IDE) Protocol

Indicate if the protocol involves an Investigational New Drug Application (IND) or Investigational Device Exemption (IDE) under US Food and Drug Administration regulations(*Will not be made public - for administrative purposes only.*)

IND/IDE Grantor

FDA center to which the IND or IDE was submitted, i.e., Center for Drug Evaluation and Research (CDER) or Center for Biologics Evaluation and Research (CBER) for INDs; Center for Devices and Radiological Health (CDRH) for IDEs. Select one. (*Will not be made public - for administrative purposes only.*)

IND/IDE Number
Number assigned to an Investigational New Drug Application (IND) or Investigational Device Exemption (IDE). (*for administrative purposes only.*)

IND/IDE Serial Number
Use the serial number from the first submission of the protocol to the IND or IDE. (*for administrative purposes only.*)

Has Expanded Access?
Indicate whether any non-protocol access is to be provided for the investigational drug or device. If so, an Expanded Access record should also be created for this IND/IDE.

Collaborators

Other organizations providing support, including funding, design, implementation, data analysis and reporting. The data provider is responsible for confirming all collaborators before listing them. Provide up to 10 full names of collaborating organizations.

Brief Summary

Short description of the primary purpose of the protocol intended for the lay public. Include a brief statement of the study hypothesis.

Detailed Description

Extended description of the protocol, including more technical information (as compared to the Brief Summary) if desired. Do not include the entire protocol; do not duplicate information recorded in other data elements, such as eligibility criteria or outcome measures.

Study Start Date

Date that enrollment to the protocol begins.

Completion Date

Final date on which data was (or is expected to be) collected. A "Type" menu is also included, with options Anticipated and Actual. For active studies, set Type to Anticipated and specify the expected completion date, updating the date as needed over the course of the study. Upon study completion, change Type to Actual and update the date if necessary.

Record Verification Date

Definition: Date the protocol information was last verified. Verification date is shown along with organization name on ClinicalTrials.gov to indicate to the public whether the information is being kept current, particularly recruiting status and contact information.

Overall Recruitment Status

Overall accrual activity for the protocol. Select one.

- Not yet recruiting: participants are not yet being recruited
- Recruiting: participants are currently being recruited
- Enrolling by invitation: participants are being (or will be) selected from a predetermined population
- Active, not recruiting: study is ongoing (i.e., patients are being treated or examined), but participants are not currently being recruited or enrolled

- Completed: the study has concluded normally; participants are no longer being examined or treated (i.e., last patient's last visit has occurred)
- Suspended: recruiting or enrolling participants has halted prematurely but potentially will resume
- Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated
- Withdrawn: study halted prematurely, prior to enrollment of first participant

Why Study Stopped

For suspended, terminated or withdrawn studies, provide a *brief* explanation of why the study has been halted or terminated. If desired, use brief summary or detailed description to provide additional information.

Expanded Access Status

Status indicating availability of an experimental drug or device outside any clinical trial protocol. This data element is only applicable for Expanded Access records (see Expanded Access under Study Type). Select one.

- Available: expanded access is currently available for this treatment.
- No longer available: expanded access was available for this treatment previously but is not currently available and will not be available in the future.
- Temporarily not available: expanded access is not currently available for this treatment, but is expected to be available in the future.
- Approved for marketing: this treatment has been approved for sale to the public.

Primary Purpose

Reason for the protocol

- Treatment: protocol designed to evaluate one or more interventions for treating a disease, syndrome or condition
- Prevention: protocol designed to assess one or more interventions aimed at preventing the development of a specific disease or health condition
- Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition
- Supportive Care: protocol designed to evaluation interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
- Screening: protocol designed to assess or examine methods of identifying a condition (or risk factors for a condition) in people who are not yet known to have the condition (or risk factor).
- Health Services Research: protocol design to evaluate the delivery, processes, management, organization or financing of health care.
- Basic Science: protocol designed to examine the basic mechanism of action (e.g., physiology, biomechanics) of an intervention.
- Other: describe in Detailed Description.

Study Design

Intervention assignments

- Single Group: single arm study
- Parallel: participants are assigned to one of two or more groups in parallel for the duration of the study
- Cross-over: participants receive one of two alternative interventions during the initial phase of the study and receive the other intervention during the second phase of the study
- Factorial: two or more interventions, each alone and in combination, are evaluated in parallel against a control group

Study Phase

Phase of investigation, as defined by the US FDA for trials involving investigational new drugs. Select only one.

N/A: for trials without phases

Phase 0: exploratory trials, involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening studies, microdose studies). See FDA guidance on exploratory IND studies for more information.

Phase 1: includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients

Phase 1/Phase 2: for trials that are a combination of phases 1 and 2

Phase 2: includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks

Phase 2/Phase 3: for trials that are a combination of phases 2 and 3

Phase 3: includes expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide an adequate basis for physician labeling

Phase 4: post-marketing studies to delineate additional information including the drug's risks, benefits, and optimal use

Number of Arms

Number of intervention groups (enter 1 for single-arm study).

Masking

Knowledge of intervention assignments

- Open: no masking is used. All involved know the identity of the intervention assignment.
- Single Blind: one party, either the investigator or participant, is unaware of the intervention assignment; also called single-masked study.
- Double Blind: both participants and investigators are unaware of the intervention assignment

  If Single Blind or Double Blind is selected, check the role(s) that are to be masked: Subject, Caregiver, Investigator or Outcomes Assessor.

Allocation

Participant selection

- N/A: single arm study
- Randomized Controlled Trial: participants are assigned to intervention groups by chance
- Nonrandomized Trial: participants are expressly assigned to intervention groups through a non-random method, such as physician choice

Study Classification

Type of primary outcome or endpoint that the protocol is designed to evaluate. Select one.

- N/A: not applicable
- Safety: show if the drug is safe under conditions of proposed use
- Efficacy: measure of an intervention's influence on a disease or health condition
- Safety/Efficacy
- Bio-equivalence: scientific basis for comparing generic and brand name drugs
- Bio-availability: rate and extent to which a drug is absorbed or otherwise available to the treatment site in the body
- Pharmacokinetics: the action of a drug in the body over a period of time including the process of absorption, distribution and localization in tissue, biotransformation, and excretion of the compound
- Pharmacodynamics: action of drugs in living systems
- Pharmacokinetics/dynamics
-

Enrollment

Number of subjects in the trial. A "Type" menu is also included, with options Anticipated and Actual. For active studies, set Type to Anticipated and specify the expected enrollment, updating the number as needed over the course of the study. Upon study completion, change Type to Actual and update the enrollment if necessary.

Keywords

Words or phrases that best describe the protocol. Keywords help users find studies in the database. Use NLM's Medical Subject Heading (MeSH) controlled vocabulary terms where appropriate. Be as specific and precise as possible. Avoid acronyms and abbreviations.

Study Population Description

For observational studies only, a description of the population from which the groups or cohorts will be selected (e.g., primary care clinic, community sample, residents of a certain town).

Sampling Method

For observational studies only, select one and explain in Detailed Description.

- Probability Sample: exclusively random process to guarantee that each participant or population has specified chance of selection, such as simple random sampling, systematic sampling, stratified random sampling, cluster sampling, and consecutive patient sampling
- Non-Probability Sample: any of a variety of other sampling processes, such as convenience sampling or invitation to volunteer

Eligibility Criteria

Summary criteria for participant selection. The preferred format includes lists of inclusion and exclusion criteria as shown below.

Example:

Inclusion Criteria:
- Clinical diagnosis of Alzheimer's Disease
- Must be able to swallow tablets

Exclusion Criteria:
- Insulin dependent diabetes
- Thyroid disease

Gender

Physical gender of individuals who may participate in the protocol. Select one.

- Both: both female and male participants are being studied
- Female: only female participants are being studied
- Male: only male participants are being studied

Minimum Age

Minimum age of participants. Provide a number and select a unit of time (years, months, weeks, days, hours or minutes). Select "N/A (No limit)" if no minimum age is indicated.

Maximum Age

Maximum age of participants. Provide a number and a unit of time (years, months, weeks, days, hours or minutes). Select "N/A (No limit)" if no maximum age is indicated.

Accepts Healthy Volunteers

Indicate if persons who have not had the condition(s) being studied or otherwise related conditions or symptoms, as specified in the eligibility requirements, may participate in the study. Select Yes/No.

Facility

Multiple locations may be specified.

- Name: Full name of the organization where the protocol is being conducted.
  Examples: UCLA Eye Institute; Springfield Memorial Hospital
- City
- State/Province
- Postal Code
- Country

Investigators (at the protocol location)

- First Name
- Middle Initial
- Last Name
- Degrees
- Role: Site Principal Investigator or Site Sub-Investigator (pick one)

Facility Contact

- First Name
- Middle Initial
- Last Name
- Degree
- Phone: office phone of the facility contact person. Use the format 123-456-7890 within the United States and Canada. Otherwise, provide the country code.
- Ext: phone extension, if needed
- Email: electronic mail address of the facility contact person

Central Contact

Person providing centralized, coordinated recruitment information for the entire study.

- First Name
- Middle Initial
- Last Name
- Degree
- Phone: Office phone of the central contact person. Use the format 123-456-7890 within the United States and Canada. Otherwise, provide the country code.
- Ext: phone extension, if needed
- Email: electronic mail address of the central contact person

Overall Study Officials

Person(s) responsible for the overall scientific leadership of the protocol, including study principal investigator.

- First Name
- Middle Initial
- Last Name
- Degree
- Official's Role: Position or function of the official. Select one (Study Chair/Study Director/Study Principal Investigator).
- Organizational Affiliation: Full name of the official's organization. If none, specify Unaffiliated.

References

Citations to publications related to the protocol: background and/or results. Provide either the unique PubMed Identifier (PMID) of an article or enter the full bibliographic citation.

Results Reference

Indicate if the reference provided reports on results from this clinical research study.

Recruitment Status

Protocol accrual activity at a facility. Select one.

- Not yet recruiting: participants are not yet being recruited
- Recruiting: participants are currently being recruited
- Enrolling by invitation: participants are being (or will be) selected from a predetermined population
- Active, not recruiting: study is ongoing (i.e., patients are being treated or examined), but participants are not currently being recruited or enrolled
- Completed: the study has concluded normally; participants are no longer being examined or treated

(i.e., last patient's last visit has occurred)
- Suspended: recruiting or enrolling participants has halted prematurely but potentially will resume
- Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated
- Withdrawn: study halted prematurely, prior to enrollment of first participant

Links

A Web site directly relevant to the protocol may be entered, if desired. Do not include sites whose primary goal is to advertise or sell commercial products or services. *Links to educational, research, government, and other non-profit Web pages are acceptable.*

Applicant Details

The person making the application, can be contacted should there be any query on the application.

Principal Investigator

Address to include contact telephone and fax numbers and email id. For a multi-center study, enter the contact Name and Address information for the lead Principal Investigator or overall Trial Coordinator.

Site/s of study

First list all site/s within the country including the site address as well as the complete address, email, telephone number and Fax No of responsible contact person at each site. For multi-country trials, list all site/s within each country (if available) including the site address as well as the complete address, email, telephone number and Fax No of responsible contact person at each site.

Method of generating randomization sequence

The method used to generate the random allocation sequence. The main purpose of randomization is to eliminate selection bias and balance known and unknown confounding factors in order to create a control group that is as similar as possible to the treatment group. Methods for randomly assigning participants to groups, which limits bias, include the use of a table of random numbers and a computer program that generates random numbers. Methods of assignment that are prone to bias include alternating assignment or assignment by date of birth or hospital admission number.

Method of allocation concealment

Any method whereby allocation of the next participant is known beforehand, such as alternation or an open list of random numbers, may prompt investigators to select the next participant according to conscious or unconscious needs that can seriously bias the selection process. Concealment of the randomization sequence is critical to prevent selection bias. Adequate allocation concealment is a pre-requisite for adequate blinding. Adequate allocation concealment methods include:

- centralized (e.g. allocation by a central office unaware of subject characteristics)
- pharmacy-controlled randomization
- pre-numbered or coded identical containers which are administered serially to participants
- on-site computer system combined with allocations kept in a locked unreadable computer file
- sequentially numbered, sealed, opaque envelopes

Allocation concealment that is prone to bias include

- alternation
- case record numbers
- dates of birth or day of the week
- an open list of random numbers and
- any procedure that is entirely transparent before allocation

Phase of Trial

Phases of investigation, usually applied to a drug trial Phase 1: includes initial study to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing does, and to gain early evidence of effectiveness; may include healthy participants and/or patients (such as those testing anticancer or anti-HIV drugs) . Trials are often dose ranging trials which are done to determine the maximum dose of a new medication that can be safely given to a patient.

Phase 1 / **Phase 2**: for trials that are at a combined stage of phases 1 and 2Phase 2: includes controlled clinical study conducted to evaluate/test the effectiveness of a new drug/medication or intervention for a particular indication or indications in patients with the disease or condition being studied and to determine the common short-term side effects and risks

Phase 2 / **Phase 3**: for trials that are at a combined stage of phases 2 and 3

Phase 3: includes expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of a new drug/medication or intervention, including possible adverse reactions. It is also to provide an adequate basis for physician labeling

Phase 3 /**Phase 4**: for trials that are at a combined stage of phases 3 and 4

Phase 4: post-marketing study to delineate additional information. Trials are done to monitor the toxicity, risks, utility, benefits and optimal use after the efficacy of the drug/medication or intervention has been proven

Not applicable: this selection is for a non-drug trial

Appendix III – Schema Map

Field name / Register	WHO	ICMJE	CT.gov	ISRCTN	CTRI	ACTR	type	aliases	subfields
Primary Register	✔						single selection of primary register names		
Trial ID #	✔	✔	✔	✔	✔	✔	text	UID, Organization's Unique ID(CT.gov), Unique Trial Number (ICMJE), Protocol/Serial Number (ISRCTN), UTRN (CTRI)	
Date of Registration in Primary Register	✔	✔					date	Trial Registration Date (ICMJE)	
Secondary ID#s	✔	✔	✔	✔	✔	✔	record list	MEDLINE Identifier (CT.gov), ISRCTN	(Issuing Authority, id #, date assigned)
Source(s) of Monetary or Material Support	✔	✔		✔	✔		text list	Funding Sources (ICMJE), Sources of Funding (ISRCTN)	
Primary Sponsor	✔	✔	✔	✔	✔	✔	text	Sponsor (CT.gov, ISRCTN)	
Funding Source(s)						✔	record list (max: 20 entries)		(type, name, address, country)
Secondary Sponsor(s)	✔	✔	✔		✔	✔	text list	Collaborators (CT.gov)	
Other Collaborator(s)						✔	record list (max: 20 entries)		(type, name, address, country)
Applicant				✔			record		(title, forename, surname, address, town, country, zip, tel, fax, email, reference)
Contact for Public Queries	✔	✔	✔	✔	✔	✔	text	Responsible Contact Person (ICMJE), Central Contact (CT.gov), Contact (ISRCTN), Contact Person (CTRI)	(name, email, phone, address)
Contact for Scientific Queries	✔	✔	✔		✔	✔	text	Research Contact Person (ICMJE), Overall Study Officials (CT.gov), Contact Person (CTRI)	(name, email, phone, address, role, affiliation)
Contact Person responsible for updating information						✔			(name, email, phone, fax, address, affiliation)
Facility			✔		✔		record	Sites of Study (CTRI)	(name, city, state/province, postal code, country)
Facility Contact			✔				record		(name, middle initial, last name, degree, phone, ext, email)
Facility Contact Backup			✔				text		
Investigators			✔		✔		record list	Principal Investigator (CTRI)	(name, middle initial, last name, degree, role[principal|sub])
Public Title	✔	✔	✔		✔	✔	text	Brief Title (CT.gov), Title of the study (ICMJE, CTRI)	
Scientific Title	✔	✔	✔	✔	✔	✔	text	Official Title (CT.gov), Official scientific title (ICMJE), Title of trial (ISRCTN), Study Title in PICO format (ACTR)	Acronym
Countries of Recruitment	✔			✔	✔	✔	multi-selection list of country names		
Health Condition(s) or Problem(s) Studied	✔	✔	✔	✔	✔	✔	text (CT.gov: use MeSH)	Condition (CT.gov, ICMJE), disease/condition/study domain (ISRCTN)	
Condition category and code						✔	multi-selection list of (category,code)		
Brief Summary			✔			✔	text		

Field name / Register	WHO	ICMJE	CT.gov	ISRCTN	CTRI	ACTR	type	aliases	subfields
Intervention(s)	✔	✔	✔	✔	✔	✔	record list	Intervention and comparator agent (CTRI)	(name, details)
Intervention Name			✔				text		
Intervention Description			✔				text		
Intervention Type			✔				single selection from (drug, device, biological/vaccine, procedure/surgery, radiation, behavioral, genetic, dietary, other)	Intervention Code (ACTR)	
Intervention Code						✔	multi-selection {max. 3} from (N/A, Diagnosis, Early detection/ screening, prevention, treatment: drugs, treatment: surgery, treatment: devices, treatment: other, rehabilitation, lifestyle, behaviour, other interventions)	Intervention Type (CT.gov)	
Comparator/ control treatment						✔	text		
Inclusion Criteria	✔	✔		✔	✔	✔	text	Key Inclusion Criteria (ACTR)	
Exclusion Criteria	✔	✔		✔	✔	✔	text	Key Exclusion Criteria (ACTR)	
Patient Information Material				✔			text		
Control group						✔	single selection from (placebo, active, uncontrolled, historical, dose comparison)		
Study Type	✔				✔		single selection from (single arm, randomized, non-randomized)	Study Design (ISRCTN)	
Study Type		✔					single selection from (randomized, non-randomized), type of masking (double-blind, single-blind), type of control, group assignment)		(randomization, masking, control, assignment)
Study Type			✔			✔	single selection from (Interventional, Observational, Expanded Access)		
Method of generating randomization sequence					✔		single selection from (Coin toss, lottery, toss of dice, shuffling cards, Random number table , Computer generated randomization, Permuted block randomization, fixed Permuted block randomization, variable Stratified randomization, Stratified block randomization , Adaptive randomization, Other)	Sequence Generation (ACTR)	other:(detailed description)
Sequence Generation						✔	text	Method of generating randomization sequence (CTRI)	
Date of First Enrollment	✔	✔	✔	✔	✔	✔	date	Study Start Date (CT.gov), Anticipated Trial Start Date (ICMJE), Anticipated Start/End Date (ISRCTN), Anticipated or actual start date (ACTR)	
Target Sample Size	✔		✔	✔		✔	number	Enrollment (CT.gov), Target Number of participants (ISRCTN)	
Completion Date			✔		✔		date, type (anticipated, actual)	Last Follow-up Date, Estimated Duration of Trial (CTRI)	(date, type)
Record Verification Date			✔				date		
Target Sample Size	✔	✔			✔		number		
Recruitment Status	✔	✔		✔	✔	✔	single selection from (pending, active, temporary halt, closed)	Overall Recruitment Status (CT.gov), Status (ISRCTN), Status of Trial (CTRI)	
Overall Recruitment Status			✔				single selection from (not yet recruiting, recruiting, no longer recruiting, enrolling by invitation, completed, suspended, terminated, withdrawn)	Recruitment Status (WHO, ICMJE)	
Primary Outcome(s)	✔	✔	✔	✔	✔	✔	record list	Measure+Time Frame (CT.gov)	(name, timepoints)
Key Secondary Outcomes	✔	✔	✔	✔	✔	✔	record list		(name, timepoints)
Research ethics review		✔		✔	✔	✔	boolean (yes/no)	Ethics Approval (ISRCTN), Approval Status (CTRI)	ACTR: (name, address, country, date, HREC number) max 50 entries

Field name / Register	WHO	ICMJE	CT.gov	ISRCTN	CTRI	ACTR	type	aliases	subfields
Regulatory Clearence from DCGI					✔		boolean (yes/no)		
IND/IDE Protocol			✔				boolean (yes/no)	Trial ID #, UID	
IND/IDE Grantor			✔				text		
IND/IDE Number			✔				number		
IND/IDE Serial Number			✔				number		
Expanded Access			✔				boolean (yes/no)		
Expanded Access Status			✔				single selection from (available, no longer available, temporarily not available, approved for marketing)		
Board Approval			✔				single selection from (not submitted, pending, approved, exempt, denied, not required) and number		(status, number)
Board Name			✔		✔		text	Name of ethics committee (CTRI)	
Board Affiliation			✔				text		
Board Contact			✔				text		(phone, ext, email, address)
Data Monitoring Committee			✔				boolean (yes/no)		
Oversight Authorities			✔				record list		(country, organization name)
Detailed Description			✔				text		
Why Study Stopped			✔				text		
Primary Purpose			✔				single selection from (treatment, prevention, diagnostic, supportive care, screening, health services research, basic research, other)	Purpose of Study (ACTR)	other:(detailed description)
Purpose of Study						✔	single selection from (treatment, prevention, diagnosis, educational/counselling/training)	Primary Purpose (CT.gov)	
Purpose (Observational)						✔	single selection from (natural history, screening, psychosocial)		
Duration (Observational)						✔	single selection from (longitudinal, cross-sectional)		
Study Phase			✔		✔	✔	single selection from (N/A, 0, 1, 1/2, 2, 2/3, 3, 4)	Phase of Trial (CTRI), Phase (ACTR)	
Study Design (Interventional)			✔			✔	single selection from (single group, parallel, cross-over, factorial, other)	study type:assignment (ICMJE), assignment (ACTR)	other:(detailed description)
Study Design (Observational)			✔				single selection from (cohort, case-control, case-only, case-crossover, ecologic or community studies, family-based, other)		other:(detailed description)
Study Hypothesis				✔	✔		text	Brief Summary (CTRI)	
Number of Arms			✔				number		
Masking			✔				single selection from (open, single blind, double blind)	study type:masking (ICMJE), Blinding and Masking (CTRI),	
Masking/blinding						✔	open or blinded. if blinded: who is blinded is single selection from (subjects, therapist/clinician, assessor, data analyst)	Masking	
Allocation			✔			✔	single selection from (N/A, randomized, non-randomized)	study type (ICMJE), allocation to intervention (ACTR)	
Method of allocation concealment					✔	✔	single selection from (centralized, pharmacy-controlled randomization, pre-numbered, on-site computer system, sequence number sealed opaque envelopes)	allocation concealment procedures (ACTR)	
Selection						✔	single selection from (convenience sample, defined population, random sample, case control)		
Study Classification			✔			✔	single selection from (N/A, safety, efficacy, safety/efficacy, bio-equivalence, bio-availability, pharmacokinetics, pharmacodynamics, pharmacokinetics/pharmacodynamics)	Endpoint, type of endpoints (ACTRsychosocial	

Field name / Register	WHO	ICMJE	CT.gov	ISRCTN	CTRI	ACTR	type	aliases	subfields
Time Perspective			✔			✔	single selection from (prospective, retrospective, cross-sectional, other)	Timing (ACTR)	other:(detailed description)
Biospecimen Retention			✔				single selection from (none retained, with DNA, without DNA)		
Biospecimen Description			✔				text		
Number of groups/cohorts			✔				number		
Arm/Group Intervention			✔				record list		(number, type, description)
Keywords			✔				text list (MeSH vocabulary)		
Study Population Description			✔				text		
Sampling Method			✔				single selection from (probability, non-probability)		
Eligibility Criteria			✔				text		
Eligibility Gender			✔			✔	single selection from (both, male, female)	Gender (ACTR)	
Eligibility Age			✔				(number or N/A, number or N/A)	Age (ACTR)	(minimum, maximum)
Age						✔	(min. age, max.age, unit:(years, months, weeks, days, hours, no limit, N/A, not stated))	Eligibility Age (CT.gov)	
Accept Healthy Volunteers			✔			✔	boolean (yes/no)		
Links			✔	✔		✔	record list	Trial Website (ACTR, ISRCTN)	(URL, description)
References			✔			✔	record list	Publications (ISRCTN), Presentations/Publications (ACTR)	(citation, identifier, reference_trial)